It was found that two companies applied for a combination drug license that combines Forxiga (Dapagliflozin Propanediol Hydrate, AZ), a SGLT-2 inhibitory family, leading the diabetes treatment market, and Januvia (Sitagliptin Phosphate Hydrate, MSD), a DPP-4 inhibitory class.

Combination of Forxiga+Januvia has not yet been approved in Korea. It is expected that market success is expected if commercialized.

According to the MFDS on the 30th, a combination of Dapagliflozin Propanediol Hydrate　 (10mg)-Sitagliptin Phosphate Hydrate (100mg) was applied for approval on the 30th of last month and the 1st of this month. Dongkoo recently applied for the same ingredient to the MFDS. As Donggu Bi